Acute kidney injury (AKI) is a common medical problem, especially in patients undergoing cardiovascular procedures. The risk of kidney damage has multiple determinants and is often related to or exacerbated by intravenous or intra-arterial iodinated contrast. Contrast-induced AKI (CI-AKI) has been associated with an increased risk of subsequent myocardial infarction, stroke, the development of heart failure, rehospitalization, progression of chronic kidney disease, end-stage renal disease, and death. Statins have been studied extensively in the setting of chronic kidney disease and they have been shown to reduce albuminuria, but they have had no effect on the progressive reduction of glomerular filtration or the need for renal replacement therapy. Several meta-analyses have shown a protective effect of short-term statin administration on CI-AKI and led to two large randomized controlled trials evaluating the role of rosuvastatin in the prevention of CI-AKI in high-risk patients with acute coronary syndrome and diabetes mellitus. Both trials showed a benefit of rosuvastatin prior to contrast administration in a statin-naive patient population. In aggregate, these studies support the short-term use of statins specifically for the prevention of CI-AKI in patients undergoing coronary angiography with or without percutaneous coronary intervention.

Keywords:
Statins, Acute kidney injury, Contrast
1.
Hsu RK, et al: Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol 2013;24:37-42.
2.
Nash K, Hafeez A, Hou S: Hospital-acquired renal insufficiency. Am J Kidney Dis 2002;39:930-936.
3.
Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012;81:442-448.
4.
Chertow GM, et al: Preoperative renal risk stratification. Circulation 1997;95:878-884.
5.
Thakar CV, et al: Improved survival in acute kidney injury after cardiac surgery. Am J Kidney Dis 2007;50:703-711.
6.
Toth PP, Dayspring TD: Drug safety evaluation of rosuvastatin. Expert Opin Drug Saf 2011;10:969-986.
7.
Teichholz LE: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2003;138:1008, author reply 1008-1009.
8.
Graham DJ, et al: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-2590.
9.
Melli G, Chaudhry V, Cornblath DR: Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore) 2005;84:377-385.
10.
de Meijer AR, et al: Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med 2003;29:1121-1125.
11.
Vidt DG: Statins and proteinuria. Curr Atheroscler Rep 2005;7:351-357.
12.
Wu Y, et al: Effects of rosuvastatin and atorvastatin on renal function: meta-analysis. Circ J 2012;76:1259-1266.
13.
Sandhu S, et al: Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 2006;17:2006-2016.
14.
Douglas K, O'Malley PG, Jackson JL: Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 2006;145:117-124.
15.
Strippoli GF, et al: Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008;336:645-651.
16.
Navaneethan SD, et al: HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009:CD007784.
17.
Pappy R, et al: Effect of statin therapy on contrast-induced nephropathy after coronary angiography: a meta-analysis. Int J Cardiol 2011;151:348-353.
18.
Zhang L, et al: Efficacy of statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis of randomised controlled trials. Int J Clin Pract 2011;65:624-630.
19.
Zhang BC, Li WM, Xu YW: High-dose statin pretreatment for the prevention of contrast-induced nephropathy: a meta-analysis. Can J Cardiol 2011;27:851-858.
20.
Zhou Y, et al: Short-term, high-dose statins in the prevention of contrast-induced nephropathy: a systematic review and meta-analysis. Clin Nephrol 2011;76:475-483.
21.
Li Y, et al: Efficacy of short-term high-dose statin in preventing contrast-induced nephropathy: a meta-analysis of seven randomized controlled trials. PLoS One 2012;7:e34450.
22.
Leoncini M, et al: Early high-dose rosuvastatin for contrast-induced nephropathy prevention in acute coronary syndrome: results from the PRATO-ACS Study (Protective effect of Rosuvastatin and Antiplatelet Therapy On contrast-induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). J Am Coll Cardiol 2014;63:71-79.
23.
Han Y, et al: Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease. J Am Coll Cardiol 2014;63:62-70.
24.
Liao JK: Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002;110:285-288.
25.
Sidaway JE, et al: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 2004;15:2258-2265.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.